Literature DB >> 15160405

Cure fraction estimation from the mixture cure models for grouped survival data.

Binbing Yu1, Ram C Tiwari, Kathleen A Cronin, Eric J Feuer.   

Abstract

Mixture cure models are usually used to model failure time data with long-term survivors. These models have been applied to grouped survival data. The models provide simultaneous estimates of the proportion of the patients cured from disease and the distribution of the survival times for uncured patients (latency distribution). However, a crucial issue with mixture cure models is the identifiability of the cure fraction and parameters of kernel distribution. Cure fraction estimates can be quite sensitive to the choice of latency distributions and length of follow-up time. In this paper, sensitivity of parameter estimates under semi-parametric model and several most commonly used parametric models, namely lognormal, loglogistic, Weibull and generalized Gamma distributions, is explored. The cure fraction estimates from the model with generalized Gamma distribution is found to be quite robust. A simulation study was carried out to examine the effect of follow-up time and latency distribution specification on cure fraction estimation. The cure models with generalized Gamma latency distribution are applied to the population-based survival data for several cancer sites from the Surveillance, Epidemiology and End Results (SEER) Program. Several cautions on the general use of cure model are advised. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15160405     DOI: 10.1002/sim.1774

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  18 in total

1.  Single-arm phase II trial design under parametric cure models.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2015-04-01       Impact factor: 1.894

2.  Modelling population-based cancer survival trends using join point models for grouped survival data.

Authors:  Binbing Yu; Lan Huang; Ram C Tiwari; Eric J Feuer; Karen A Johnson
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-04       Impact factor: 2.483

3.  A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.

Authors:  Tim S Grant; Darren Burns; Christopher Kiff; Dawn Lee
Journal:  Pharmacoeconomics       Date:  2020-04       Impact factor: 4.981

4.  Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up.

Authors:  Megan Othus; Aasthaa Bansal; Harry Erba; Scott Ramsey
Journal:  Value Health       Date:  2020-07-31       Impact factor: 5.725

5.  An accelerated failure time mixture cure model with masked event.

Authors:  Jenny J Zhang; Molin Wang
Journal:  Biom J       Date:  2009-12       Impact factor: 2.207

6.  Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States.

Authors:  Angela B Mariotto; Ruth Etzioni; Marc Hurlbert; Lynne Penberthy; Musa Mayer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-18       Impact factor: 4.254

7.  A finite mixture survival model to characterize risk groups of neuroblastoma.

Authors:  Sally Hunsberger; Paul S Albert; Wendy B London
Journal:  Stat Med       Date:  2009-04-15       Impact factor: 2.373

8.  A multivariate cure model for left-censored and right-censored data with application to colorectal cancer screening patterns.

Authors:  Yolanda C Hagar; Danielle J Harvey; Laurel A Beckett
Journal:  Stat Med       Date:  2016-03-18       Impact factor: 2.373

9.  Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States.

Authors:  Shirley M Bluethmann; Angela B Mariotto; Julia H Rowland
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-07       Impact factor: 4.254

10.  Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer.

Authors:  Angela B Mariotto; Zhaohui Zou; Fanni Zhang; Nadia Howlader; Allison W Kurian; Ruth Etzioni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-18       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.